Northland Capmk Predicts Envoy Medical Q3 Earnings (2025)

Envoy Medical, Inc. (NASDAQ:COCH – Free Report) – Northland Capmk issued their Q3 2025 earnings per share (EPS) estimates for Envoy Medical in a report issued on Wednesday, April 23rd. Northland Capmk analyst C. Byrnes expects that the company will post earnings of ($0.35) per share for the quarter. The consensus estimate for Envoy Medical’s current full-year earnings is ($1.21) per share. Northland Capmk also issued estimates for Envoy Medical’s Q4 2025 earnings at ($0.38) EPS, FY2025 earnings at ($1.41) EPS and FY2026 earnings at ($1.67) EPS.

Separately, Ascendiant Capital Markets lifted their price target on shares of Envoy Medical from $9.00 to $9.25 and gave the company a “buy” rating in a report on Monday, April 21st.

Get Our Latest Report on Envoy Medical

Envoy Medical Trading Up 1.4 %

Shares of COCH opened at $1.48 on Friday. The firm has a market cap of $31.56 million, a price-to-earnings ratio of -1.05 and a beta of 2.35. The stock has a 50 day moving average of $1.38 and a 200-day moving average of $1.75. Envoy Medical has a 52 week low of $1.21 and a 52 week high of $5.42.

Envoy Medical (NASDAQ:COCH – Get Free Report) last posted its quarterly earnings results on Friday, March 28th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.12). The company had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.07 million.

Institutional Investors Weigh In On Envoy Medical

Several large investors have recently made changes to their positions in the company. DSG Capital Advisors LLC acquired a new stake in Envoy Medical in the fourth quarter worth about $234,000. Citadel Advisors LLC bought a new stake in shares of Envoy Medical during the 4th quarter worth $42,000. CIBC Private Wealth Group LLC acquired a new stake in shares of Envoy Medical during the fourth quarter worth $65,000. Finally, Lake Street Advisors Group LLC purchased a new stake in Envoy Medical during the fourth quarter valued at about $65,000. Institutional investors and hedge funds own 8.59% of the company’s stock.

Envoy Medical Company Profile

(Get Free Report)

Envoy Medical, Inc, a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc in September 2023.

Featured Articles

• Five stocks we like better than Envoy Medical
• 3 Warren Buffett Stocks to Buy Now
• Short Sellers Gave Up on These 3 Names Recently
• Utilities Stocks Explained – How and Why to Invest in Utilities
• 3 Boring Stocks Outperforming the Market This Year
• Conference Calls and Individual Investors
• If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy

Receive News & Ratings for Envoy Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envoy Medical and related companies with MarketBeat.com's FREE daily email newsletter.